[Form 4/A] BridgeBio Pharma, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Atlassian Corporation (TEAM) – Form 4 Insider Transaction

Co-CEO, Director and 10% owner Michael Cannon-Brookes reported three open-market sales of the company’s Class A common stock on 30 June 2025. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20 February 2025.

• Total shares sold: 7,665 (4,653 + 2,748 + 264)
• Weighted-average prices: $203.38, $202.70 and $204.12, respectively
• Aggregate value (approx.): $1.56 million
• Post-sale holdings: the trust (CBC Co Pty Ltd as trustee for the Cannon-Brookes Head Trust) now holds 3,012 TEAM shares; direct ownership lines show no remaining shares for the disclosed accounts.

The filing indicates the sales span a narrow $202–$204 price range, suggesting routine portfolio rebalancing rather than a reaction to unforeseen events. No derivative security activity was reported.

While the absolute dollar amount is modest relative to Cannon-Brookes’ multi-billion-dollar stake, any insider sale by a founder-CEO can attract investor attention. The use of a 10b5-1 plan provides an affirmative defense against allegations of trading on non-public information.

Positive

• Use of Rule 10b5-1 plan demonstrates compliance and reduces insider-trading risk.
• Founder retains significant ownership, signalling continued long-term commitment.

Negative

• Insider sale by CEO/founder may be viewed negatively by some investors despite small size.

Insights

Securities Analyst

TL;DR Minor founder sale (7.7k shares, $1.6 M) via 10b5-1; immaterial to ownership, limited valuation impact.

This Form 4 shows Michael Cannon-Brookes disposing of 7,665 TEAM shares at roughly $203 per share. Post-sale, he still owns well over 10% of Atlassian, so the reduction is negligible in percentage terms. The pre-scheduled 10b5-1 plan mitigates signalling risk, and the narrow trading range indicates orderly execution. From a valuation standpoint, the transaction does not alter float meaningfully and should be viewed as routine liquidity management.

Governance & Risk Analyst

TL;DR Insider sale by CEO is a mild negative sentiment indicator, but scale too small for strategic concern.

Founders selling shares can raise governance red flags; however, the relative size (~$1.6 M) versus Cannon-Brookes’ multi-billion holding (<0.05% of his stake) limits impact. The presence of a 10b5-1 plan and ongoing 10% ownership alleviate potential worry. No accompanying negative disclosures were filed, reducing the likelihood of information asymmetry. Overall risk impact is low.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valantine Hannah

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/28/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/13/2024

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/28/2021		P		1,542	A	$12.68	1,542	D
Common Stock	12/28/2021		P		796	A	$13.16	2,687	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Hannah A. Valantine, M.D.	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Atlassian (TEAM) shares did Michael Cannon-Brookes sell on 30 June 2025?

He sold a total of 7,665 Class A shares across three transactions.

At what prices were the TEAM shares sold?

Weighted-average sale prices were $203.38, $202.70 and $204.12.

Was the insider sale part of a 10b5-1 trading plan?

Yes, the trades were executed under a Rule 10b5-1 plan adopted on 20 Feb 2025.

How many TEAM shares does the trust still hold after the sale?

The trust’s reported holding is 3,012 shares following the transactions.

Did the Form 4 report any derivative security transactions?

No, Table II shows no derivative activity for the period.